SUPN

#1826
Supernus Pharmaceuticals, Inc. - Common Stock
44.0 7 USD
+0.01%
Market Price
Sector: Healthcare
Base: USD
Profit Currency: USD
Daily Range
43.67
44.13
Year Range
42.45
59.68
Daily Change
+0.75%
Monthly Change
-12.65%
6 month change
-18.79%
Year Change
-18.39%
Previous Close
43.7 4
Open
44.0 1
Low
43.6 7
High
44.1 3
Volume
387
Open full chart

Financials

Overview Statement Statistics Documents

2026

Current report, Q3 FY2026
SUPERNUS PHARMACEUTICALS, INC. current report, Q3 FY2026
8-K
Current report, Q3 FY2026
SUPERNUS PHARMACEUTICALS, INC. current report, Q3 FY2026
8-K
Current report, Q3 FY2026
SUPERNUS PHARMACEUTICALS, INC. current report, Q3 FY2026
8-K
Current report, Q3 FY2026
SUPERNUS PHARMACEUTICALS, INC. current report, Q3 FY2026
8-K
Current report, Q3 FY2026
SUPERNUS PHARMACEUTICALS, INC. current report, Q3 FY2026
8-K
Quarterly report, Q2 FY2026
SUPERNUS PHARMACEUTICALS, INC. quarterly report, Q2 FY2026
10-Q
Current report, Q2 FY2026
SUPERNUS PHARMACEUTICALS, INC. current report, Q2 FY2026
8-K
Current report, Q2 FY2026
SUPERNUS PHARMACEUTICALS, INC. current report, Q2 FY2026
8-K
Current report, Q2 FY2026
SUPERNUS PHARMACEUTICALS, INC. current report, Q2 FY2026
8-K
Current report, Q2 FY2026
SUPERNUS PHARMACEUTICALS, INC. current report, Q2 FY2026
8-K

SUPERNUS PHARMACEUTICALS, INC. current report, 15 June 2021

Full document

Business Context and Reporting Period

This Form 8-K Current Report from Supernus Pharmaceuticals, Inc. covers the date of June 15, 2021. The filing documents the results of the Company's Annual Meeting of Stockholders held on that date. As of April 16, 2021, there were 53,018,637 shares of common stock outstanding and entitled to vote.

Key Financial Metrics

This filing is a corporate governance report regarding stockholder votes and does not contain financial performance data. Consequently, there are no reported values for revenue, profit, cash flow, margins, debt, or liquidity in this document.

Material Changes

No material financial changes are reported in this filing. The document details the outcome of four specific proposals voted upon by stockholders:

  • Proposal 1 (Election of Class III Directors): Both nominees, Georges Gemayel, Ph.D., and John M. Siebert, Ph.D., were elected. Dr. Siebert received significantly higher support (43.6M votes for) compared to Dr. Gemayel (35.6M votes for).
  • Proposal 2 (Ratification of Auditors): Stockholders ratified the appointment of KPMG LLP as the independent public accounting firm for the fiscal year ending December 31, 2021, with 47.2 million votes in favor.
  • Proposal 3 (Executive Compensation): The non-binding advisory vote on executive compensation was approved with 42.8 million votes in favor.
  • Proposal 4 (2021 Equity Incentive Plan): Stockholders approved the adoption of the 2021 Equity Incentive Plan with 41.0 million votes in favor.

Guidance, Outlook, and Risks

This filing does not provide management commentary, financial guidance, outlook, or a discussion of risks and contingencies. It strictly reports the tabulation of votes from the Annual Meeting.

Key Facts for Investor Verification

  • Verify the final vote counts for the election of Class III Directors, noting the significant difference in withheld votes between the two nominees.
  • Confirm the ratification of KPMG LLP as the auditor for the 2021 fiscal year.
  • Review the approval status of the new 2021 Equity Incentive Plan, which received majority support.
  • Note that this document contains no financial statements; refer to the Company's 10-K or 10-Q filings for financial performance data.

News